Protocatechualdehyde inhibitsreceptor activator of nuclear factor kappa‐B ligand‐induced osteoclastogenesis and attenuates lipopolysaccharide‐induced inflammatory osteolysis

Inflammatory osteolysis as a consequence of chronic bacterial infection underlies several lytic bone conditions, such as otitis media, osteomyelitis, septic arthritis, periodontitis, periprosthetic infection, and aseptic loosening of orthopedic implants. In consideration of the lack of effective preventive or treatments options against infectious osteolysis, the exploitation of novel pharmacological compounds/agents is critically required. The present study assessed the effect of protocatechualdehyde (PCA), a natural occurring polyphenolic compound with diverse biological activities including but not limited to antibacterial and antiinflammatory properties, on nuclear factor‐κB ligand (RANKL)‐induced osteoclastogenesis in vitro and lipopolysaccharide (LPS)‐induced bone loss in vivo. In the present study, it was found that PCA potently inhibited RANKL‐induced osteoclast formation, fusion, and activation toward bone resorption in a dose‐dependent manner via the suppression of the ERK/c‐Fos/nuclear factor of activated T‐cells, cytoplasmic 1 signaling axis. It was further demonstrated that the in vivo administration of PCA could effectively protect mice against the deleterious effects of LPS‐induced calvarial bone destruction by attenuating osteoclast formation and activity in a dose‐dependent manner. Collectively, these findings provided evidence for the potential therapeutic application of PCA in the prevention and treatment of infectious osteolytic conditions, and potentially other osteoclast‐mediated bone diseases.